FDA批准-话题@MedSci

#FDA批准#

870篇内容 | 7863人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1839541, encodeId=fd9618395410f, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准Nivolumab，肝癌开启免疫治疗新时代, objectType=article, longId=115404, objectId=402f11540435, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=402f11540435, replyNumber=0, likeNumber=67, createdTime=2018-06-07, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=402f11540435, moduleTitle=FDA批准Nivolumab，肝癌开启免疫治疗新时代, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=402f11540435)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839565, encodeId=42c51839565b9, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准罗氏帕妥珠单抗用于早期乳腺癌辅助治疗, objectType=article, longId=124356, objectId=ebed1243566e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ebed1243566e, replyNumber=0, likeNumber=78, createdTime=2018-01-17, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ebed1243566e, moduleTitle=FDA批准罗氏帕妥珠单抗用于早期乳腺癌辅助治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ebed1243566e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839559, encodeId=41de18395599b, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准了葛兰素史克的用于治疗罕见自身免疫性疾病的生物制剂, objectType=article, longId=123375, objectId=cf7e1233e57b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cf7e1233e57b, replyNumber=0, likeNumber=67, createdTime=2018-05-04, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cf7e1233e57b, moduleTitle=FDA批准了葛兰素史克的用于治疗罕见自身免疫性疾病的生物制剂, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cf7e1233e57b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839523, encodeId=272e183952316, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准AML新靶向治疗药物, objectType=article, longId=107512, objectId=441a10e512b8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=441a10e512b8, replyNumber=0, likeNumber=80, createdTime=2017-09-07, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=441a10e512b8, moduleTitle=FDA批准AML新靶向治疗药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=441a10e512b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839531, encodeId=32fe183953131, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准浙江医药复方蒿甲醚片, objectType=article, longId=112843, objectId=9e0b1128432c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9e0b1128432c, replyNumber=0, likeNumber=66, createdTime=2018-02-05, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9e0b1128432c, moduleTitle=FDA批准浙江医药复方蒿甲醚片, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9e0b1128432c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839553, encodeId=7d2f1839553f2, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=CFDA批准上市雅美罗®（托珠单抗注射液），用于治疗全身型幼年特发性关节炎, objectType=article, longId=121792, objectId=c46f121e9221, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c46f121e9221, replyNumber=0, likeNumber=78, createdTime=2018-07-10, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c46f121e9221, moduleTitle=CFDA批准上市雅美罗®（托珠单抗注射液），用于治疗全身型幼年特发性关节炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c46f121e9221)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839532, encodeId=065c183953258, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准第五个生物类似物, objectType=article, longId=113333, objectId=ced6113333ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ced6113333ba, replyNumber=0, likeNumber=80, createdTime=2017-12-07, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ced6113333ba, moduleTitle=FDA批准第五个生物类似物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ced6113333ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839552, encodeId=278918395527a, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=CFDA批准上市洛珊®（布南色林片）审评概述, objectType=article, longId=121791, objectId=97d3121e9121, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=97d3121e9121, replyNumber=0, likeNumber=72, createdTime=2018-02-02, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=97d3121e9121, moduleTitle=CFDA批准上市洛珊®（布南色林片）审评概述, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=97d3121e9121)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839530, encodeId=cb6818395303c, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=勃林格殷格翰的修美乐生物类似药获FDA批准, objectType=article, longId=112593, objectId=1db4112593da, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1db4112593da, replyNumber=0, likeNumber=55, createdTime=2018-08-11, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1db4112593da, moduleTitle=勃林格殷格翰的修美乐生物类似药获FDA批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1db4112593da)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839496, encodeId=8fe4183949623, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准又一通用型CAR-T疗法进入临床试验, objectType=article, longId=91772, objectId=85b191e7297, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=85b191e7297, replyNumber=0, likeNumber=122, createdTime=2017-04-02, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=85b191e7297, moduleTitle=FDA批准又一通用型CAR-T疗法进入临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=85b191e7297)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839492, encodeId=3b08183949248, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准IL17A抗体brodalumab, objectType=article, longId=89400, objectId=759d894008d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=759d894008d, replyNumber=0, likeNumber=65, createdTime=2017-12-01, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=759d894008d, moduleTitle=FDA批准IL17A抗体brodalumab, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=759d894008d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839544, encodeId=a65b183954453, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准利伐沙班标签更新, objectType=article, longId=118532, objectId=82b911853251, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=82b911853251, replyNumber=0, likeNumber=56, createdTime=2017-12-03, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=82b911853251, moduleTitle=FDA批准利伐沙班标签更新, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=82b911853251)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839528, encodeId=f6241839528df, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准免疫球蛋白用于狂犬病治疗, objectType=article, longId=111394, objectId=99831113944f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=99831113944f, replyNumber=0, likeNumber=68, createdTime=2018-06-10, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=99831113944f, moduleTitle=FDA批准免疫球蛋白用于狂犬病治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=99831113944f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839490, encodeId=47ce18394901c, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=喜讯！安进新一代肾脏病药物Parsabiv获美国FDA批准, objectType=article, longId=88562, objectId=56ba8856271, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=56ba8856271, replyNumber=0, likeNumber=87, createdTime=2017-07-28, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=56ba8856271, moduleTitle=喜讯！安进新一代肾脏病药物Parsabiv获美国FDA批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=56ba8856271)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839478, encodeId=8e0418394e879, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=详解2016年FDA批准的20款创新药（名称、活性成分、适应症……）, objectType=article, longId=84803, objectId=0e798480319, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0e798480319, replyNumber=0, likeNumber=74, createdTime=2017-03-17, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0e798480319, moduleTitle=详解2016年FDA批准的20款创新药（名称、活性成分、适应症……）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0e798480319)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839501, encodeId=20291839501e4, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准第三个PARPi卵巢癌新药niraparib, objectType=article, longId=93844, objectId=f2fd938442c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f2fd938442c, replyNumber=0, likeNumber=79, createdTime=2017-11-29, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f2fd938442c, moduleTitle=FDA批准第三个PARPi卵巢癌新药niraparib, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f2fd938442c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839519, encodeId=2ce4183951957, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准降低乳腺癌复发风险的新药, objectType=article, longId=105915, objectId=e809105915b4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e809105915b4, replyNumber=0, likeNumber=68, createdTime=2017-08-18, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e809105915b4, moduleTitle=FDA批准降低乳腺癌复发风险的新药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e809105915b4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839514, encodeId=2ca21839514ec, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=研发17年!治疗皮肤感染的新型抗生素获FDA批准, objectType=article, longId=102872, objectId=a5981028e216, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a5981028e216, replyNumber=0, likeNumber=66, createdTime=2018-05-01, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a5981028e216, moduleTitle=研发17年!治疗皮肤感染的新型抗生素获FDA批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a5981028e216)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839525, encodeId=197e1839525ba, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准的用于实体瘤治疗的单抗类药物盘点, objectType=article, longId=108485, objectId=b60510848596, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b60510848596, replyNumber=0, likeNumber=68, createdTime=2018-03-09, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b60510848596, moduleTitle=FDA批准的用于实体瘤治疗的单抗类药物盘点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b60510848596)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839484, encodeId=fd831839484d8, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准Cepheid新一代MRSA检测设备上市, objectType=article, longId=86652, objectId=95f4866521b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=95f4866521b, replyNumber=0, likeNumber=52, createdTime=2017-06-25, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=95f4866521b, moduleTitle=FDA批准Cepheid新一代MRSA检测设备上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=95f4866521b)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

FDA批准

2020-05-29发表于威斯康星

仁医06 (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准Nivolumab，肝癌开启免疫治疗新时代

2018-06-07

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准罗氏帕妥珠单抗用于早期乳腺癌辅助治疗

2018-01-17

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准了葛兰素史克的用于治疗罕见自身免疫性疾病的生物制剂

2018-05-04

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准AML新靶向治疗药物

2017-09-07

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准浙江医药复方蒿甲醚片

2018-02-05

bugit (审核中...)

前往app查看评论内容

#FDA批准#

CFDA批准上市雅美罗®（托珠单抗注射液），用于治疗全身型幼年特发性关节炎

2018-07-10

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准第五个生物类似物

2017-12-07

bugit (审核中...)

前往app查看评论内容

#FDA批准#

CFDA批准上市洛珊®（布南色林片）审评概述

2018-02-02

bugit (审核中...)

前往app查看评论内容

#FDA批准#

勃林格殷格翰的修美乐生物类似药获FDA批准

2018-08-11

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准又一通用型CAR-T疗法进入临床试验

2017-04-02

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准IL17A抗体brodalumab

2017-12-01

仁医06 (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准利伐沙班标签更新

2017-12-03

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准免疫球蛋白用于狂犬病治疗

2018-06-10

bugit (审核中...)

前往app查看评论内容

#FDA批准#

喜讯！安进新一代肾脏病药物Parsabiv获美国FDA批准

2017-07-28

bugit (审核中...)

前往app查看评论内容

#FDA批准#

详解2016年FDA批准的20款创新药（名称、活性成分、适应症……）

2017-03-17

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准第三个PARPi卵巢癌新药niraparib

2017-11-29

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准降低乳腺癌复发风险的新药

2017-08-18

bugit (审核中...)

前往app查看评论内容

#FDA批准#

研发17年!治疗皮肤感染的新型抗生素获FDA批准

2018-05-01

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准的用于实体瘤治疗的单抗类药物盘点

2018-03-09

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准Cepheid新一代MRSA检测设备上市

2017-06-25

科室
- - 订阅+
  - 更多科室
工具
服务